Second Sight Medical (NSDQ:EYES) said today that the results from the 3-year study of its Argus II Retinal Prosthesis System were published in the Austrian journal Clinical and Experimental Optometry.
The study used functional low-vision observer rated assessments, an instrument specifically developed for retinal prosthesis patients with severe loss of vision or blindness, to assess 26 patients equipped with the Argus II.
Patients in the study reported a significant improvement in 24 of 35 tasks performed with the device on, while 2 tasks of 25 reported a decrease in outcome. The remaining 9 total tasks showed no significant change in outcome.
“We are thrilled, yet not surprised, with the results of this study. Since the beginning, we have heard from the majority of individuals with the Argus II that our technology has changed their life and greatly enhanced their ability to perform tasks and activities of daily life. This study validates the positive feedback we’ve been receiving from our recipients all along,” CEO Will McGuire said in prepared remarks.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
The post Second Sight touts publication of 3-year Argus II study appeared first on MassDevice.
from MassDevice http://ift.tt/1mG9JKX
Cap comentari:
Publica un comentari a l'entrada